These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 23969737)

  • 41. Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice.
    Kosztyu P; Kuchar M; Cerny J; Barkocziova L; Maly M; Petrokova H; Czernekova L; Liskova V; Raskova Kafkova L; Knotigova P; Masek J; Turanek J; Maly P; Raska M
    EBioMedicine; 2019 Sep; 47():247-256. PubMed ID: 31544770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lessons learned from HIV-1 vaccine trials: new priorities and directions.
    McMichael AJ; Haynes BF
    Nat Immunol; 2012 Apr; 13(5):423-7. PubMed ID: 22513323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies for eliciting HIV-1 inhibitory antibodies.
    Tomaras GD; Haynes BF
    Curr Opin HIV AIDS; 2010 Sep; 5(5):421-7. PubMed ID: 20978384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralizing antibodies to HIV-1 induced by immunization.
    McCoy LE; Weiss RA
    J Exp Med; 2013 Feb; 210(2):209-23. PubMed ID: 23401570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.
    Liu CC; Zheng XJ; Ye XS
    ChemMedChem; 2016 Feb; 11(4):357-62. PubMed ID: 26762799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current views on the potential for development of a HIV vaccine.
    Cohen KW; Frahm N
    Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.
    Haynes BF; Moody MA; Liao HX; Verkoczy L; Tomaras GD
    Trends Mol Med; 2011 Feb; 17(2):108-16. PubMed ID: 21112250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?
    Braibant M; Barin F
    Retrovirology; 2013 Oct; 10():103. PubMed ID: 24099103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
    Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
    J Virol; 2017 May; 91(9):. PubMed ID: 28202762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlates of broadly neutralizing antibody development.
    Abela IA; Kadelka C; Trkola A
    Curr Opin HIV AIDS; 2019 Jul; 14(4):279-285. PubMed ID: 31107283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Passive and active antibody studies in primates to inform HIV vaccines.
    Hessell AJ; Malherbe DC; Haigwood NL
    Expert Rev Vaccines; 2018 Feb; 17(2):127-144. PubMed ID: 29307225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A global approach to HIV-1 vaccine development.
    Stephenson KE; Barouch DH
    Immunol Rev; 2013 Jul; 254(1):295-304. PubMed ID: 23772627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2984-7. PubMed ID: 23602538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
    Moore PL; Gorman J; Doria-Rose NA; Morris L
    Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Antibody Response against HIV-1.
    Overbaugh J; Morris L
    Cold Spring Harb Perspect Med; 2012 Jan; 2(1):a007039. PubMed ID: 22315717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.